Abstract:Objective The androgen receptor-targeting drugs abiraterone acetate and enzalutamide have shown positive results as treatments for metastatic castration-resistant prostate cancer (mCRPC). Therefore, a meta-analysis was conducted to compare the efficacy and safety of abiraterone acetate and enzalutamide in patients with mCRPC. Methods We retrieved relevant articles from PubMed, Cochrane, and EMBASE published before December 31, 2020. Eleven articles were initially selected, and four phase III, double-blind, randomized controlled trials of abiraterone acetate and enzalutamide that involved 5199 patients with mCRPC were included. The end points were time to prostate-specific antigen progression (TTPP), according to the prostate-specific antigen working group criteria; overall survival (OS); and radiographic progression-free survival (rPFS). Results Four randomized, controlled clinical trials involving 5199 patients were included in this study. The results of the meta-analysis showed that compared with placebo alone, abiraterone significantly improved OS (HR=0.69, 95% CI: 0.60-0.8, P<0.00001), rPFS (HR=0.64, 95% CI: 0.57-0.71, P < 0.00001), and TTPP (HR=0.52, 95% CI: 0.45-0.59, P < 0.00001) in patients with mCRPC. Compared with placebo, enzalutamide significantly improved OS (HR=0.67, 95% CI: 0.59-0.75, P<0.00001), rPFS (HR=0.33, 95% CI: 0.29-0.37, P< 0.00001), and TTPP (HR=0.19, 95% CI: 0.17-0.22, P < 0.00001). An indirect comparison was performed to compare the efficacy of abiraterone and enzalutamide. The results showed that there was no significant difference between abiraterone and enzalutamide with regard to improving the OS of patients with mCRPC (HR=1.03, 95% CI: 0.854-1.242). Enzalutamide was superior to abiraterone with regard to improving rPFS in patients with mCRPC (HR=0.516, 95% CI: 0.438-0.608). With regard to improving TTPP, the efficacy of enzalutamide was better than that of abiraterone (HR=0.365, 95% CI: 0.303-0.441). In sAE, there was no difference between abiraterone and enzalutamide (P=0.21, I 2 = 38%). Conclusions Compared with placebo, both abiraterone and enzalutamide significantly prolonged OS, rPFS, and TTPP in patients with mCRPC. There was no difference in safety between abiraterone and enzalutamide. In addition, enzalutamide had better efficacy than abiraterone with regard to improving rPFS and TTPP but not OS, but the level of evidence was low. Therefore, a large direct comparison trial is needed to compare the efficacy of the two drugs. Systematic Review Registration PROSPERO, identifier (CRD42021226808)

Inhibition of Autophagy Improves the Efficacy of Abiraterone for the Treatment of Prostate Cancer

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model

Simultaneous Autophagy and Androgen Receptor Inhibition in a Prostate Cancer Xenograft Model

Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer after Docetaxel Failure: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Bridging Study

Effect of Androgen Blockade on Autophagy and Apoptosis in Bladder Cancer UM-UC-3 Cells

Inhibition Of Androgen Induces Autophagy In Benign Prostate Epithelial Cells

Targeting Androgen Receptor Leads to Suppression of Prostate Cancer Via Induction of Autophagy

Inhibition of autophagy promotes apoptosis and enhances anticancer efficacy of adriamycin via augmented ROS generation in prostate cancer cells

Observation of Serological Index and Efficacy of Abiraterone Hydrochloride Tablets Combined with Endocrine Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

Inhibition of autophagy leads to increased apoptosis in LNCaP cells under androgen deprivation conditions

Androgen Receptor Antagonist Bicalutamide Induces Autophagy and Apoptosis Via ULK2 Upregulation in Human Bladder Cancer Cells.

Effect of resveratrol on autophagy in prostate cancer PC-3 cells

Ambra1 Induces Autophagy and Desensitizes Human Prostate Cancer Cells to Cisplatin.

Autophagy protects LNCaP cells under androgen deprivation conditions.

Efficacy and Prognostic Factors of Abiraterone Combined with Prednisone Treating Metastatic Castration-Resistant Prostate Cancer Patients

Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response

Elevated Levels of Autophagy-Related Marker ULK1 and Mitochondrion-Associated Autophagy Inhibitor LRPPRC Are Associated with Biochemical Progression and Overall Survival after Androgen Deprivation Therapy in Patients with Metastatic Prostate Cancer

CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy

Instrumental and transcriptome analysis reveals the chemotherapeutic effects of doxorubicin-loaded black phosphate nanosheets on abiraterone-resistant prostate cancer

Combination of the NRF2 Inhibitor and Autophagy Inhibitor Significantly Inhibited Tumorigenicity of Castration-Resistant Prostate Cancer